Loading
Theriva Biologics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by SHALLCROSS STEVEN A, was filed 08 Jun 2023.
Theriva Biologics, Inc.: what insiders have been doing
Theriva Biologics, Inc. is a Health Care company. Its directors and officers file their transactions with SEC (Form 4). The past year has been quiet: not a single insider filing for Theriva Biologics, Inc. The previous disclosure was published on 8 June 2023.
Looking back to 2006, when coverage begins, insiders filed 117 purchases and 9 sales.
Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and EssilorLuxottica. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
140
Thresholds
n/a
Buy Volume
€14M
117 ops. · all time
Sell Volume
€6M
9 ops. · all time
Since the insiders bought
- -62.9%Entry US$17.50 · Close at T+365 US$6.50
- -35.1%Entry US$21,962.50 · Close at T+365 US$14,262.50
- +39.7%Entry US$11,900.00 · Close at T+365 US$16,625.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.21
Analyst consensus
2 analystsUS$1.00Target US$2.50(+1102%)US$4.00
Income statement
EBITDA-US$23.9M
Net income-US$23.7M0.0% margin
Valuation
PER (trailing)0.3x
PER (forward)-1.0x
P/Book0.8x
Beta1.19
Balance sheet & cash
Market capUS$9.5M
Total debtUS$2.6M
Free Cash Flow-US$16.7M
Debt / Equity29%
Profitability & ownership
ROE-101.9%
ROA-21.3%
% insiders1.6%
% institutions4.3%
Last declaration on 8 June 2023
Declarations140 total
14,000 shares@ US$0.69316.1% of flowCommon StockSEC:0001104659-23-069136:0
Canonical exit: 5 Sept 2023 (T+90)
26,000 shares@ US$0.632810.4% of flowCommon StockSEC:0001104659-23-068719:0
Canonical exit: 4 Sept 2023 (T+90)
25,000 shares@ US$1.04316.3% of flowCommon StockSEC:0001104659-23-018901:0
Canonical exit: 11 May 2023 (T+90)
25,000 shares@ US$0.940514.4% of flowCommon StockSEC:0001104659-23-010108:0
Canonical exit: 3 May 2023 (T+90)
25,000 shares@ US$0.87313.5% of flowCommon StockSEC:0001104659-23-006677:0
Canonical exit: 25 Apr 2023 (T+90)
25,000 shares@ US$0.748211.6% of flowCommon StockSEC:0001104659-23-005546:0
Canonical exit: 20 Apr 2023 (T+90)
100,000 shares@ US$0.43727.7% of flowCommon StockSEC:0001104659-23-000023:0
Canonical exit: 29 Mar 2023 (T+90)
50,000 shares@ US$0.4919100.0% of flowCommon StockSEC:0001104659-21-064047:0
Canonical exit: 8 Aug 2021 (T+90)
50,000 shares@ US$0.415710.0% of flowCommon StockSEC:0001144204-19-041677:0
Canonical exit: 21 Nov 2019 (T+90)
30,265 shares@ US$0.6720.6% of flowCommon StockSEC:0001567619-19-008334:1
3,737 shares@ US$0.662.5% of flowCommon StockSEC:0001567619-19-008334:2
11,413 shares@ US$0.677.8% of flowCommon StockSEC:0001567619-19-008334:0
9,909 shares@ US$0.666.6% of flowCommon StockSEC:0001567619-19-008334:3
26,080 shares@ US$0.6517.1% of flowCommon StockSEC:0001567619-19-008334:4
69,161 shares@ US$0.6545.4% of flowCommon StockSEC:0001567619-19-008334:5
228,773 shares@ US$0.09100.0% of flowCommon StockSEC:0001144204-17-015198:0
300,000 sharesCommon StockSEC:0001144204-16-135295:0
937,500 shares@ US$3.20Common StockSEC:0001140361-15-034452:0
Canonical exit: 1 Dec 2015 (T+90)
10,842 shares@ US$0.09Common StockSEC:0001144204-15-020893:0
10,000 shares@ US$1.35Common StockSEC:0001144204-14-033539:0
Canonical exit: 20 Aug 2014 (T+90)
5,003,025 shares@ US$1.43Common StockSEC:0001144204-14-027196:0
175,177 shares@ US$2.86Common StockSEC:0001144204-14-026434:0
87,935 shares@ US$2.98Common StockSEC:0001144204-14-026434:1
500,000 shares@ US$1.00Common StockSEC:0001140361-13-047006:0
Canonical exit: 17 Mar 2014 (T+90)
2,000,000 shares@ US$1.00Common StockSEC:0001140361-13-047006:1
Canonical exit: 17 Mar 2014 (T+90)
25 of 140 declarations
About Theriva Biologics, Inc.
Theriva Biologics, Inc. is a biopharmaceutical company focused on developing innovative therapies for serious diseases. It is listed on the XNAS market.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
